- Exchange: -
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
YM Biosciences Inc
FQA:GR
Ticker Delisted
Snapshot for YM Biosciences Inc (FQA)
| Open: | - | Day's Range: | - | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | - | 52wk Range: | 1.112 - 2.218 | 1-Yr Rtn: | - |
Key Statistics for FQA
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(06/2013) | - |
| Relative P/E vs. DAX | - |
| Earnings Per Share (CAD) (ttm) | - |
| Est. EPS (CAD) (06/2013) | -0.2420 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 0 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | - |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for FQA
Company Profile & Key Executives for FQA
YM Biosciences Inc. is developing cancer drugs based on technologies licensed primarily from international academic centers. The Company is currently developing a small molecule chemopotentiator for metastatic breast cancer, an EGFr humanized monoclonal antibody, and a GnRH cancer vaccine. YM is also supporting the preclinical development of additional cancer products.
| Nick GloverPresident/CEO | Leonard Vernon "Len"VP:Finance & Administration |
| Mark KowalskiVP:Regulatory Affairs | Wendy ChapmanVP:Clinical Operations |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
FQA News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page